LYRA
Lyra TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LYRA Profile
Lyra Therapeutics, Inc.
A clinical-stage therapeutics company offering a platform that enable precise, sustained and local delivery of medications to the ear, nose and throat passages and other diseased tissues
Pharmaceutical
11/21/2005
05/01/2020
NASDAQ Stock Exchange
30
12-31
Common stock
480 Arsenal Way, Watertown, MA 02472
--
Lyra Therapeutics, Inc., was incorporated as a Delaware corporation on November 21, 2005. The company is a clinical-stage therapeutic company focused on the development and commercialization of novel integrated medicines and delivery solutions for the local treatment of ear patients. The company's proprietary technology platform, XTreo, is designed to deliver drugs directly, accurately and continuously directly to affected tissues with a single administration. The company's initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymer matrices designed to provide sinus access for up to six months of continuous drug therapy for the treatment of chronic sinusitis through brief, non-invasive in-office procedures.
